NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

ODT

Odonate Therapeutics Inc. Nasdaq Global Select
$3.33
Open: $3.2 High: $3.42 Low: $3.16 Close: $3.26
Range: 2021-04-19 - 2021-04-20
Volume: 1,641,229
Market: Extended-hours
Powered by Finage Stock APIDelayed data
ODT
Odonate Therapeutics Inc. 4747 Executive Drive San Diego CA, 92121 http://www.odonate.com
Odonate Therapeutics Inc is a pharmaceutical company which is engaged in the development of therapeutics which improves and extend the lives of patients with cancer. It is developing tesetaxel an chemotherapy agent used in the treatment of cancer.
  • CEO: Kevin C. Tang
  • Employees: 60
  • Sector: Healthcare
  • Industry: Biotechnology
ODT News
Latest news about the ODT
  • 3 Critical Things Investors Should Look for Before Buying Clinical-Stage Biotech Stocks

    In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss three critical things investors should look for before buying clinical-stage biotech stocks. Keith Speights: There is some news from last week that you and I didn't get a chance to talk about.

    View More →
  • Odonate Therapeutics (ODT) is Oversold: Can It Recover?

    Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

    View More →
  • Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

    View More →
  • Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't?

    Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.

    View More →
  • Why GRPN Stock And ODT Stock Are Trading Lower Today

    Groupon Inc (NASDAQ: GRPN) shares are trading lower Monday after the company announced a proposed private offering of $200 million of convertible senior notes. Groupon acts as the middleman between consumers and merchants, offering a variety of products and services at discounts via its online store. The company is best known for offering consumers daily deals in the form of online vouchers from local merchants. Odonate Therapeutics Inc (NASDAQ: ODT) shares are trading lower after the company said it would discontinue the development of its Tesetaxel. Odonate is engaged in the development of therapeutics which improve and extend the lives of patients with cancer. The company mainly focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs, taxanes, which are widely used in the treatment of cancer including breast cancer. See more from BenzingaClick here for options trades from BenzingaWhat's Happening With UPST Stock And ROKU Stock Today?Why Tesla, Nio, Nikola, Blink Charging And Xpeng Stock Are Popping Off Today© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Odonate Therapeutics stock plummets toward record low after plan to 'wind down' operations

    Shares of Odonate Therapeutics Inc. plummeted 79.0% in active afternoon trading Monday, after the pharmaceutical company said it will wind down operations following disappointing data from its cancer treatment. The company said it determined, following feedback from the Food and Drug Administration in a pre-New Drug Application (pre-NDA) meeting, that tesetaxel, an orally administered chemotherapy agent, is unlikely to receive FDA approval. "Therefore, the company is discontinuing the development of tesetaxel and will wind down the operations of the company," the company said in a statement. Since going public in December 2017 at an initial public offering price of $24, the stock has traded in a closing price range of $11.78 (Dec. 27, 2018) to $45.63 (June 16, 2020); on Friday, the stock closed at $19.03. The stock has lost 73.9% over the past three months, while the S&P 500 has gained 7.0%.

    View More →
  • Why Odonate Therapeutics Stock Is Crashing Today

    Shares of Odonate Therapeutics (NASDAQ: ODT) were crashing 78% as of 11:38 a.m. EDT on Monday. The huge drop came after Odonate announced that it's discontinuing the development of tesetaxel and will "wind down the operations of the Company." Today's news underscores the risks involved with investing in clinical-stage biotech stocks.

    View More →
  • Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel

    Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company. The Company will work with clinical sites to transition patients in ongoing tesetaxel clinical studies to appropriate alternative therapies.

    View More →
  • Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020

    Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020.

    View More →
  • Craig Johnson Is The Independent Director of Odonate Therapeutics, Inc. (NASDAQ:ODT) And Just Spent US$51k On Shares

    Even if it's not a huge purchase, we think it was good to see that Craig Johnson, the Independent Director of Odonate...

    View More →
  • Is ODT A Good Stock To Buy Now According To Hedge Funds?

    Is Odonate Therapeutics, Inc. (NASDAQ:ODT) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

    View More →
  • BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

    NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia. “We are delighted to welcome Dr. Vacirca as a member of our Board of Directors, especially given his impressive leadership within the oncology community,” said Dr. Lan Huang, Founder and Chief Executive Officer of BeyondSpring. “In addition to his many years as an accomplished oncology clinician, Dr. Vacirca also has extensive experience as a key business leader in the oncology market, including as CEO of a large community oncology practice, New York Cancer & Blood Specialists. His demonstrated success in being able to collaborate with different groups of stakeholders in the oncology market is unique and very notable. Dr. Vacirca’s deep engagement within the oncology community will be of much benefit to BeyondSpring.”Jeffrey Vacirca, MD, FACP is a board-certified hematologist and oncologist and serves as CEO and Chairman of the Board of New York Cancer & Blood Specialists. Dr. Vacirca is the immediate past president of the Community Oncology Alliance (COA) and is Medical Director for International Oncology Network (ION) at AmerisourceBergen and for Oncology Network Development at Mt. Sinai Health Network. Dr. Vacirca serves on the board of directors of OneOncology, the American Red Cross of Greater New York, New York Cancer Foundation, and is chairman of the board of directors of New York Cancer Foundation. He is also co-founder & former Vice Chairman of Odonate Therapeutics (NASDAQ: ODT), and Director & Chair of the Compensation Committee of Spectrum Pharmaceuticals (NASDAQ: SPPI).Dr. Vacirca added, “Joining the BeyondSpring Board will provide me the opportunity to participate in improving the standard of care for cancer patients by making plinabulin, in combination with pegfilgrastim, available to prevent chemotherapy-induced neutropenia and help ensure that patients are more likely to complete their planned chemotherapy regimen to achieve the optimal clinical outcome. I am also excited about the ongoing Phase 3 trial with plinabulin in NSCLC that will potentially demonstrate the anti-tumor effects of the product and could open up treatment options for other solid tumors.”About BeyondSpring  BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform utilizing the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.Media ContactsInvestor Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 617-430-7577 arr@lifesciadvisors.comMedia Contact: Darren Opland, Ph.D. LifeSci Communications +1 646-627-8387 darren@lifescicomms.com

    View More →
  • Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

    Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients with cancer, today announced that positive results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer (MBC), were presented in an oral presentation at the 2020 San Antonio Breast Cancer Symposium (SABCS). The results were presented by Joyce O’Shaughnessy, M.D., Celebrating Women Chair in Breast Cancer Research, Baylor University Medical Center, Texas Oncology and Chair, Breast Cancer Research, US Oncology, and Co‑Principal Investigator of CONTESSA (please click here for slides).

    View More →
  • Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast Cancer

    Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of Cohort 3 of CONTESSA TRIO, which will evaluate tesetaxel monotherapy in approximately 60 non-elderly patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Cohort 3 of CONTESSA TRIO will complement Cohort 2 of CONTESSA TRIO, which is evaluating tesetaxel monotherapy in approximately 60 elderly patients with HER2-negative MBC.

    View More →
  • Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020

    Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will host a virtual Investor and Analyst Event on Friday, December 11, 2020, at 1:00 p.m. CT / 2:00 p.m. ET. The event will follow the presentation of the results of CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer, at the 2020 SABCS, which is scheduled to occur at 8:45 a.m. CT / 9:45 a.m. ET on December 11, 2020 (https://www.sabcs.org/Program/Daily-Schedule/Day-4). Featured speakers will include Lee Schwartzberg, M.D., FACP, Chief Medical Director, West Cancer Center & Research Institute, and Andrew Seidman, M.D., Medical Director, Bobst International Center, Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College.

    View More →
  • ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: November 16, 2020

    NEW YORK, NY / ACCESSWIRE / November 16, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc.

    View More →
  • ODT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 16, 2020 in the Class Action Filed on Behalf of Odonate Therapeutics, Inc. Limited Shareholders

    New York, New York--(Newsfile Corp. - November 16, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Odonate Therapeutics, Inc. (NASDAQ: ODT) alleging that the Company violated federal securities laws.Class Period: December 7, 2017 and April 21, 2020Lead Plaintiff Deadline: November 16, 2020Learn more about your recoverable losses in ODT:http://www.kleinstocklaw.com/pslra-1/odonate-therapeutics-inc-loss-submission-form?id=10969&from=5The filed complaint alleges that Odonate Therapeutics, Inc. made materially false and/or misleading statements ...

    View More →
  • FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    Los Angeles, California--(Newsfile Corp. - November 16, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therapeutics, Inc. (NASDAQ: ODT) ("Odonate" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 7, 2017 and August 21, ...

    View More →
  • FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / November 16, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therapeutics, Inc.

    View More →
  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Odonate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 16, 2020 - ODT

    New York, New York--(Newsfile Corp. - November 16, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) ("Odonate") between December 7, 2017 and April 21, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Southern District of California. To ...

    View More →